首页> 外文期刊>Japanese Journal of Pharmacology >Chronic Therapy with Nipradilol, a β-Adrenergic Blocker, Attenuated Left Ventricular Remodeling Following Myocardial Infarction in Rats
【24h】

Chronic Therapy with Nipradilol, a β-Adrenergic Blocker, Attenuated Left Ventricular Remodeling Following Myocardial Infarction in Rats

机译:尼帕地洛尔(一种β-肾上腺素能阻滞剂)的慢性治疗可减轻大鼠心肌梗死后的左心室重塑

获取原文
           

摘要

References(26) Cited-By(2) We determined whether chronic treatment with nipradilol, a β-blocker with vasodilating action, reduces left ventricular cavity dilation (LV remodeling) following myocardial infarction and improves cardiac performance. Myocardial infarction was produced by coronary artery ligation in 16-week-old female rats and then the rats were treated for 3-4 months with nipradilol (10 mg/kg/day) or vehicle (0.5% carboxymethylcellulose). The effect of nipradilol on LV remodeling was evaluated by assessing the left ventricular end-diastolic volume index (LVEDVI)and passive pressure-volume relation curve. Since LVEDVI depends on the infarct size, LVEDVI was compared between the vehicle and nipradilol-treated rats with similar infarct size (10-40%). At 3-4 months after myocardial infarct production, the left ventricular end-diastolic volume index in the vehicle-treated rats with myocardial infarction was significantly increased, compared with that in the sham-operated rats without infarction. The nipradilol-treated rats had a significantly smaller left ventricular volume index than the vehicle-treated rats (2.04±0.16 ml/kg in the vehicle-treated group vs 1.36±0.10 ml/kg in the nipradilol-treated group, P<0.01). The maximum cardiac index achieved by volume loading as an index of cardiac performance was significantly greater in the nipradilol group than the vehicle group (254.5 ± 12.6 ml/min kg in the vehicle group vs 347.9 ± 20.2 ml/min kg in the nipradilol group, P <0.01). These results suggest that chronic treatment of nipradilol attenuated left ventricular cavity dilation after myocardial infarction and improved cardiac performance.
机译:参考文献(26)Cited-By(2)我们确定尼帕地洛(一种具有血管舒张作用的β受体阻滞剂)的长期治疗是否可减少心肌梗塞后左心室扩张(LV重塑)并改善心脏性能。在16周龄的雌性大鼠中,通过冠状动脉结扎产生心肌梗塞,然后用nipradilol(10 mg / kg / day)或赋形剂(0.5%羧甲基纤维素)治疗大鼠3-4个月。通过评估左心室舒张末期容积指数(LVEDVI)和被动压力-容积关系曲线,评估尼帕地洛对左室重构的影响。由于LVEDVI取决于梗死面积,因此在媒介物和尼泊洛尔治疗的梗死面积相似(10-40%)的大鼠之间比较了LVEDVI。心肌梗塞发生后3-4个月,与无假梗的假手术大鼠相比,载体治疗的心肌梗死大鼠的左心室舒张末期体积指数显着增加。尼泊洛尔治疗组大鼠的左心室容积指数显着小于媒介物治疗组(媒介物治疗组为2.04±0.16 ml / kg,尼泊尔醇治疗组为1.36±0.10 ml / kg,P <0.01) 。尼泊地洛组通过容量负荷获得的最大心脏指数作为心脏表现指标显着高于媒介物组(媒介物组为254.5±12.6 ml / min kg,尼泊地洛尔组为347.9±20.2 ml / min kg, P <0.01)。这些结果表明,尼帕地洛的慢性治疗可减轻心肌梗塞后左心室腔的扩张并改善心脏性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号